All In Biotech

Drug Trial Radar · NCT01394263

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jan 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

59

Actual

Start

May 2000

Primary completion

Dec 2001

Study completion Dec 2003

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.

Conditions

  • Prostate Cancer
  • Adenocarcinoma of the Prostate

Interventions

  • Histrelin hydrogel implantDrug

    50 mg histrelin acetate in hyrogel implant

  • Zoladex goserelin implantDrug

    goserelin implant injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Suppression of testosterone via the percent of patients whose testosterone was at or below chemical castration levels (<=50 n/dL) through 52 weeks of treatment.Time frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.